+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Controlled Release Drug Delivery Market, Drug Dosage, Price & Clinical Trial Insight 2026

  • ID: 5130893
  • Clinical Trials
  • July 2020
  • Region: Global
  • Kuick Research
UP TO OFF
until Sep 30th 2020
1 of 4

FEATURED COMPANIES

  • Allergan
  • BioAlliance Pharma
  • Cosmo Pharmaceuticals
  • Elan Corporation
  • Heron Therapeutics
  • Neurim Pharmaceuticals
  • MORE

"Global Controlled Release Drug Delivery Market, Drug Dosage, Price & Clinical Trial Insight 2026" Report Highlights:

  • Global Controlled Release Drug Delivery Market: More Than US$ 70 Billion Opportunity by 2026
  • US & Europe Market Share 2019: > 65%
  • US & Europe To Double It Market Sales Opportunity by 2026
  • Number of Controlled Release Drug Available in Market: > 140 Drugs
  • Clinical Trials Insight by Company, Country, Indication & Patent: > 250 Drugs
  • Controlled Release Drugs Pricing, Patent & Dosage Insight
  • Global & Regional Trend Analysis, Future Market Opportunity Outlook
  • Global Controlled Drug Delivery Market Dynamics

The market established for the target patient segment focuses towards delivering drugs at a predetermined rate, systemically or locally for a specific period of time. Although the market is predominated by regular drugs but the continuous delivery of the drugs whose kinetics can be controlled is achieving a predictable growth curve. The market utilizes drug encapsulating devices which employ controlled release of the therapeutic agents ranging from days to months. The numerous advantages provided by market over traditional methods of drug delivery such as tailoring of rate of drug release, fragile drug protection and patient comfort and compliance is what changing the prescription pattern of the doctors towards controlled release drugs.    

Extensions supplied to the available drug market in terms of mechanical strength, increasing demand of the patient population and novel drugs capable of achieving high drug loading are some of the factors that are considered as major driving factors for the controlled release drug delivery market. Other than the above mentioned factors, the market is coupled with reduced drug toxicity which is however estimated to boost the market growth in a short period of time.

In the last few years, increasing efforts have been delivered in order to diversify the range of the drug delivery and this has been processed by increasing the association of the researchers with the daily and unmet needs of the patient population. The availability of the controlled release drug delivery system in the market has shown a great progress towards handling the situation of the complex real world as the emergence of drugs that could not regulate the complex composition of disease was hampering with the overall growth of the drug market.

The availability of controlled release drugs in oral, injectable, nasal, topical and implantable forms for the patient population is making the market more dominant than the other available markets. The emergence of the market ended the search for the novel solutions to address the therapeutics challenges as well as has provided a great concern in the biotechnology and pharmaceutical industries. The amazing perspective lined up the way of controlled released drug market represents a more personalized and efficient delivery system in the coming years.  

Although the platform that has been provided by the controlled release drug delivery market is novel but the drug delivery platform provided by market has been associated with impressive clinical pipeline. It carries the potential to treat a broad spectrum of disease such as infectious diseases, inflammatory diseases, autoimmune diseases, neurological diseases and several different types of cancer. The market is capable of offering a revolutionized treatment for the patients in order to truly modify the benefits that the patients were receiving from a long period of time.

According to the research conducted by the team, it is estimated that the market is availing safe and effective pharmacotherapeutic treatment regimen for the patient population that are in an urgent need of the drug delivery system capable of transforming their treatment schedule. Although the market is associated with significant challenges for the scientists and clinicians but the availability of technological drivers will be responsible for rapid discovery of drugs related to the market. The formulation changes and safety specifications coupled with the market is estimated to encourage the people towards its consumption. The optimistic landscape of the market guarantees the complete success of the market as well as a major competition for the drugs in the near future.  

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Allergan
  • BioAlliance Pharma
  • Cosmo Pharmaceuticals
  • Elan Corporation
  • Heron Therapeutics
  • Neurim Pharmaceuticals
  • MORE

1. Introduction to Drug Delivery Methodology
1.1 Drug Delivery Overview
1.2 Drug Delivery System

2. Introduction to Controlled Drug Delivery
2.1 Novel Drug Delivery Systems
2.2 Preamble to Controlled Drug Delivery
2.3 Drug Delivery Technology
2.3.1 First Generation
2.3.2 Second Generation
2.4 Fundamentals of Controlled Delivery
2.5 Basis for Controlled Drug Delivery

3. Controlled Drug Delivery Classification
3.1 By Delivery Systems
3.1.1 Immediate Drug Release System
3.1.2 Modified Drug Release System
3.1.3 Delayed Release System
3.1.4 Extended Release System
3.1.5 Pulsatile Drug Release System
3.2 By Technology
3.2.1 Rate Preprogrammed Drug Delivery System
3.2.2 Activation Modulated Drug Delivery System
3.2.3 Feed Back Regulated Drug Delivery System
3.2.4 Site Targeted Drug Delivery Systems
3.3 By Routes of Delivery
3.3.1 Oral Controlled Drug Delivery System
3.3.2 Nasal Controlled Drug Delivery System
3.3.3 Transdermal Controlled Drug Delivery System
3.3.4 Ocular Controlled Drug Delivery System
3.3.5 Parenteral Controlled Drug Delivery

4. Controlled Drug Delivery Mechanism of Action
4.1 Diffusion Controlled
4.2 Dissolution Controlled System
4.3 Water Penetration Controlled System
4.4 Erosion Controlled System
4.5 Ion-Exchange Controlled System

5. Material Based Approaches for Controlled Drug Delivery
5.1 Polymers
5.2 Chronopharmaceutics
5.3 Nanoparticulate Delivery System

6. Global Controlled Release Drug Clinical Pipeline Overview
6.1 Phase
6.2 Country/Region
6.3 Mode of Action
6.4 Drug class
6.5 Indication

7. Controlled Drug Delivery by Indication
7.1 Diabetes
7.2 Cancer
7.3 Cardiovascular Diseases
7.4 Neurological Disorders
7.5 Infections

8. Controlled Delivery Drug Dosage & Formulation Insight
8.1 Enteral Dosage Formulations
8.1.1 Solid Dosage Forms
8.1.2 Liquid Dosage Forms
8.1.3 Inhalation Dosage Forms
8.2 Parenteral Dosage Forms
8.2.1 Injectable Dosage Forms
8.2.2 Implantable Device
8.3 General Mechanisms of Drug Release

9. Controlled Release Drugs for Alzheimer’s Disease - Pricing, Patent & Dosage Insight
9.1 Namzaric (Extended-Release)
9.2 Namenda XR (Extended – Release)
9.3 Razadyne ER (Extended – Release)

10. Controlled Release Drugs for Parkinson’s Disease - Pricing, Patent & Dosage Insight
10.1 Gocovri (Extended- Release)
10.2 Osmolex ER (Extended - Release)

11. Controlled Release Drugs for Schizophrenia  - Pricing, Patent & Dosage Insight
11.1 Perseris (Extended – Release)
11.2 Invega (Extended – Release)
11.3 Invega Sustenna/Invega Trinza (Extended – Release)
11.4 Seroquel XR (Extended – Release)
11.5 Abilify Maintena (Extended – Release)
11.6 Aristada (Extended – Release)

12. Controlled Release Drugs for Chronic Pain - Pricing, Patent & Dosage Insight
12.1 Zohydro ER (Extended – Release)
12.2 Hysingla ER (Extended – Release)
12.3 Nucynta ER (Extended – Release)
12.4 Kadian (Extended – Release)
12.5 Arymo ER (Extended – Release)
12.6 Xtampza ER (Extended – Release)
12.7 MS Contin (Extended – Release)
12.8 Embeda (Extended – Release)

13. Controlled Release Drugs for Multiple Sclerosis - Pricing, Patent & Dosage Insight
13.1 Ampyra (Extended–Release)
13.2 Tecfidera (Delayed-Release)
13.3 Rayos (Delayed-Release)
13.4 Vumerity (Delayed-Release)

14. Controlled Release Drugs for Diabetes Mellitus Type II - Pricing, Patent & Dosage Insight
14.1 Glumetza (Extended – Release)
14.2 Glucotrol XL (Extended – Release)
14.3 Fortamet (Extended – Release)
14.4 Glucophage XR (Extended – Release)
14.5 Bydureon (Extended – Release)

15. Controlled Release Drugs for Hypertension & Angina Pectoris - Pricing, Patent & Dosage Insight
15.1 Procardia XL (Extended – Release)
15.2 Toprol XL (Extended – Release)
15.3 Adalat CC (Extended – Release)
15.4 Verelan PM (Extended – Release)
15.5 Plendil (Extended – Release)
15.6 Cardizem LA (Extended – Release)

16. Global Controlled Drug Clinical Trials Insight By Company, Indication & Phase
16.1 Unknown
16.2 Research
16.3 Preclinical
16.4 Clinical
16.5 Phase-I
16.6 Phase-I/II
16.7 Phase-II
16.8 Phase-II/III
16.9 Phase-III
16.10 Preregistration
16.11 Registered

17. Marketed Controlled Drug Clinical Insight By Company & Indication

18. Global Controlled Drug Market Overview & Recent Trends at Regional Level
18.1 US
18.2 Europe
18.3 Japan

19. Global Controlled Drug Delivery Market Dynamics
19.1 Market Drivers
19.2 Challenges to be Resolved

20. Global Controlled Drug Delivery Market Future Outlook

21. Competitive Landscape
21.1 Allergan
21.2 Amylin Pharmaceuticals
21.3 AstraZeneca
21.4 BioAlliance Pharma
21.5 Biogen
21.6 Collegium Pharmaceutical
21.7 Controlled Therapeutics (Ferring Pharmaceuticals)
21.8 Cosmo Pharmaceuticals
21.9 Egalet
21.10 Elan Corporation
21.11 Encore Therapeutics
21.12 Flamel Technologies
21.13 GlaxoSmithKline
21.14 Heron Therapeutics
21.15 iCeutica
21.16 Mithra Pharmaceuticals
21.17 Neurim Pharmaceuticals
21.18 Novartis
21.19 Orexigen Therapeutics
21.20 Otsuka Pharmaceutical
21.21 Pfizer
21.22 Purdue Pharma
21.23 Syntex Pharmaceuticals International
21.24 Takeda
21.25 Zealand Pharma

List of Figures
Figure 1-1: Characteristics of an Ideal Drug Delivery System
Figure 2-1: Limitations of the Conventional Drug Delivery Systems
Figure 2-2: Diversification of the Novel Drug Delivery Platforms
Figure 2-3: History of Drug Delivery Technology from First Generation till Third Generation
Figure 2-4: Barriers to be Overcome by the Third Generation Drug Delivery System
Figure 2-5: Demonstration of the Targeted & Non-Targeted Drug Delivery
Figure 2-6: Controlled Drug Release is by Zero Order Mechanism
Figure 3-1: Plasma Concentration v/s Time Profile in Conventional & Controlled Release
Figure 3-2: Comparison of Varied Modified Drug Release Systems
Figure 3-3: Illustration of Mechanism of Pulsatile Drug Release in Pulsincap
Figure 3-4: Classification Based Over the Technicality Erudition
Figure 3-5: Structural Differentiation among Varied Classified Drug Delivery Systems
Figure 3-6: Classification Based over the Route of Administration
Figure 4-1: Differentiation of the Two Forms of the Diffusion Controlled Mechanisms
Figure 4-2: Mechanism of Encapsulation Dissolution Controlled System
Figure 4-3: Osmotic Release of the Drug Delivery with the Controlled Mechanism
Figure 4-4: Illustration of Erosion Mechanisms Found in Matrix Systems
Figure 5-1: Categorization of Polymeric Controlled Drug Delivery Devices
Figure 5-2: Varied Nanostructures Available for the Nanoparticulate Delivery System
Figure 6-1: Global - Controlled Release Drug Clinical Pipeline by Phase (%), 2020 till 2026
Figure 6-2: Global - Controlled Release Drug Clinical Pipeline by Phase (Number), 2020 till 2026
Figure 6-3: Global - Controlled Release Drug Clinical Pipeline by Country/Region (Number), 2020 till 2026
Figure 6-4: Global - Controlled Release Clinical Drug Pipeline by Mode of Action (Number), 2020 till 2026
Figure 6-5: Global - Controlled Release Drug Clinical Pipeline by Drug Class (Number), 2020 till 2026
Figure 6-6: Global - Controlled Release Drug Clinical Pipeline by indication (Number), 2020 till 2026
Figure 7-1: Major Non-Invasive Administrative Routes of Insulin Delivery
Figure 7-2:  Layout of the Controlled Drug Delivery Approaches in Cancer Therapeutics
Figure 7-3: Controlled Drug Delivery Approaches used to Deliver Drugs to CNS
Figure 8-1: Dosage Formulations for the Controlled Drug Delivery
Figure 8-2: Mechanism of the Controlled Drug Release of the Solid Dosage Forms
Figure 8-3: Representation of Categories of Liquid Dosage Form
Figure 8-4: Mechanism of Controlled Delivery of Parenteral Dosage Forms
Figure 8-5: General Forms of Oral Controlled Release System Mechanism
Figure 8-6: Schematic Diffusion Controlled Drug Release from Inert Matrices
Figure 8-7: Demonstration of the Osmotic Pump Drug Release Mechanism
Figure 9-1: Namzaric – Price of Oral Capsule, Extended Release of Dosage 10 mg-7 mg (US$), March’ 2020
Figure 9-2: Namzaric – Price of Oral Capsule, Extended Release of Dosage 10 mg-14 mg (US$), March’ 2020
Figure 9-3: Namzaric – Price of Oral Capsule, Extended Release of Dosage 10 mg-21 mg (US$), March’ 2020
Figure 9-4: Namzaric – Price of Oral Capsule, Extended Release of Dosage 10 mg-28  mg (US$), March’ 2020
Figure 9-5: Namenda XR – Available Dosage Strengths (mg), March’ 2020
Figure 9-6: Namenda XR – Price of Oral Capsules, Extended Release 7 mg (US$), March'2020
Figure 9-7: Namenda XR – Price of Oral Capsules, Extended Release 14 mg (US$), March'2020
Figure 9-8: Namenda XR – Price of Oral Capsules, Extended Release 21 mg (US$), March'2020
Figure 9-9: Namenda XR – Price of Oral Capsules, Extended Release 28 mg (US$), March'2020
Figure 9-10: Global - Namenda XR Quarterly Sales Q1 – Q4 (US$ Million), 2017 & 2018
Figure 9-11: Razadyne ER – Available Dosage Strengths (mg), March’ 2020
Figure 9-12: Razadyne ER – Price of Oral Capsules, Extended Release 8 mg (US$), March’ 2020
Figure 9-13: Razadyne ER – Price of Oral Capsules, Extended Release 16 mg (US$), March’ 2020
Figure 9-14: Razadyne ER – Price of Oral Capsules, Extended Release 24 mg (US$), March’ 2020
Figure 10-1: Gocovri – Avaialable Dosage Strengths (mg)
Figure 10-2: Gocovri – Price of Oral Capsule, Extended Release of Dosage 68.5 mg (US$), March’ 2020
Figure 10-3: Gocovri – Price of Oral Capsule, Extended Release of Dosage 137 mg (US$), March’ 2020
Figure 10-4: Global - Gocovri Quarterly Sales Q1 – Q4 (US$ Million), 2019
Figure 10-5: Global - Gocovri Annual Sales (US$ Million), 2018 & 2019
Figure 10-6: Osmolex ER – Available Dosage Strengths (mg), March’ 2020
Figure 10-7: Osmolex ER – Price of Oral Capsules, Extended Release 129 mg (US$), March’ 2020
Figure 10-8: Osmolex ER – Price of Oral Capsules, Extended Release 193 mg (US$), March’ 2020
Figure 10-9:  Osmolex ER – Price of Oral Tablets, Extended Release 258 mg (US$), March’ 2020
Figure 10-10: Global - Selling, General & & Administrative Expenses Q1 – Q4 (US$ Million), 2018
Figure 10-11: Global - Selling, General & & Administrative Expenses Q1 – Q4 (US$ Million), 2019
Figure 10-12: Global - Osmolex ER Selling, General & Administrative Expenses Q1 (US$ Million), 2018 & 2019
Figure 10-13: Global - Osmolex ER Selling, General & Administrative Expenses Q2 (US$ Million), 2018 & 2019
Figure 10-14: Global - Osmolex ER Selling, General & Administrative Expenses Q3 (US$ Million), 2018 & 2019
Figure 10-15: Global - Osmolex ER Q4 Selling, General & Administrative Expenses (US$ Million), 2018 & 2019
Figure 11-1: Perseris: Available Dosage Strengths (mg)
Figure 11-2: Perseris: Price of 1 Subcutaneous Powder for Injection, Extended Release (US$) March’ 2020
Figure 11-3: Global - Perseris Estimated Annual Sales (US$ Million), 2019 - 2025
Figure 11-4: Invega – Available Dosage Strengths (mg)
Figure 11-5: Invega – Price of Oral Tablets, Extended Release of Dosage 1.5 mg (US$), March’ 2020
Figure 11-6: Invega – Price of Oral Tablets, Extended Release of Dosage 3 mg (US$), March’ 2020
Figure 11-7: Invega – Price of Oral Tablets, Extended Release of Dosage 6 mg (US$), March’ 2020
Figure 11-8: Invega – Price of Oral Tablets, Extended Release of Dosage 9 mg (US$), March’ 2020
Figure 11-9: Invega Sustenna – Available Dosage Strengths (mg)
Figure 11-10: Invega Trinza – Available Dosage Strengths (mg)
Figure 11-11: Invega Sustenna – Price of Intramuscular Suspension, Extended Release of Dosage 39 mg (US$), March’ 2020
Figure 11-12: Invega Sustenna – Price of Intramuscular Suspension, Extended Release of Dosage 78 mg (US$), March’ 2020
Figure 11-13: Invega Sustenna – Price of Intramuscular Suspension, Extended Release of Dosage 117 mg (US$), March’ 2020
Figure 11-14: Invega Sustenna – Price of Intramuscular Suspension, Extended Release of Dosage 156 mg (US$), March’ 2020
Figure 11-15: Invega Sustenna – Price of Intramuscular Suspension, Extended Release of Dosage 234 mg (US$), March’ 2020
Figure 11-16: Invega Trinza – Price of Intramuscular Suspension Extended Release 273 mg (US$), March’ 2020
Figure 11-17: Invega Trinza – Price of Intramuscular Suspension Extended Release 410 mg (US$), March’ 2020
Figure 11-18: Invega Trinza – Price of Intramuscular Suspension Extended Release 546 mg (US$), March’ 2020
Figure 11-19: Invega Trinza – Price of Intramuscular Suspension Extended Release 819 mg (US$), March’ 2020
Figure 11-20: US - Invega Sustenna/ Invega Trinza Quarterly Sales Q1 – Q4 (US$ Million), 2018
Figure 11-21: Global - Invega Sustenna/ Invega Trinza Quarterly Sales Q1 – Q4 (US$ Million), 2018
Figure 11-22: Global – Invega Sustenna/ Invega Trinza Regional Sales Q1 – Q4 (US$ Million), 2018
Figure 11-23: US – Invega Sustenna/ Invega Trinza Regional Sales Q1 – Q4 (US$ Million), 2019
Figure 11-24: Global – Invega Sustenna/ Invega Trinza Sales Q1 – Q4 (US$ Million), 2019
Figure 11-25: Global – Invega Sustenna/ Invega Trinza Regional Sales Q1 – Q4 (US$ Million), 2019
Figure 11-26: Seroquel XR – Available Dosage Strengths (mg)
Figure 11-27: Seroquel XR – Price of Oral Tablets, Extended Release of Dosage 50 mg (US$), March’ 2020
Figure 11-28: Seroquel XR – Price of Oral Tablets, Extended Release of Dosage 150 mg (US$), March’ 2020
Figure 11-29: Seroquel XR – Price of Oral Tablets, Extended Release of Dosage 200 mg (US$), March’ 2020
Figure 11-30: Seroquel XR – Price of Oral Tablets, Extended Release of Dosage 300 mg (US$), March’ 2020
Figure 11-31: Seroquel XR – Price of Oral Tablets, Extended Release of Dosage 300 mg (US$), March’ 2020
Figure 11-32: Global - Seroquel XR Total Annual Sales (US$ Million), 2017 - 2019
Figure 11-33: Global - Seroquel XR Quarterly Sales Q1 – Q4 (US$ Million), 2018
Figure 11-34: Global - Seroquel XR Quarterly Sales Q1 – Q4 (US$ Million), 2019
Figure 11-35: Abilify Maintena – Available Dosage Strengths (mg)
Figure 11-36: Abilify Maintena – Price of Intramuscular Powder for Injection, Extended Release for Dosage 300 mg & 400 mg (US$), March’ 2020
Figure 11-37: Global - Abilify Maintena Quarterly Sales Q1 – Q4 (US$ Million), 2018
Figure 11-38: Global - Abilify Maintena Quarterly Sales Q1 – Q3 (US$ Million), 2019
Figure 11-39: North America - Abilify Maintena Quarterly Sales Q1 – Q4 (US$ Million), 2018 & 2019
Figure 11-40: Aristada – Available Dosage Strengths (mg)
Figure 11-41: Aristada – Price of Intramuscular Suspension, Extended Release of Dosage 441 mg (US$), March’ 2020
Figure 11-42: Aristada – Price of Intramuscular Suspension, Extended Release of Dosage 662 mg (US$), March’ 2020
Figure 11-43: Aristada – Price of Intramuscular Suspension, Extended Release of Dosage 882 mg (US$), March’ 2020
Figure 11-44: Aristada – Price of Intramuscular Suspension, Extended Release of Dosage 1064 mg (US$), March’ 2020
Figure 11-45: Global – Aristada Quarterly Sales Q1-Q4 (US$ Million), 2018
Figure 11-46: Global – Aristada Quarterly Sales Q1-Q4 (US$ Million), 2019
Figure 12-1: Zohydro ER – Available Dosage Strengths (mg)
Figure 12-2: Zohydro ER – Price of Oral Capsules, Extended Release of Dosage 10 mg (US$), 2020
Figure 12-3: Zohydro ER – Price of Oral Capsules, Extended Release of Dosage 15 mg (US$), 2020
Figure 12-4: Zohydro ER – Price of Oral Capsules, Extended Release of Dosage 20 mg (US$), 2020
Figure 12-5: Zohydro ER – Price of Oral Capsules, Extended Release of Dosage 30 mg (US$), 2020
Figure 12-6: Zohydro ER – Price of Oral Capsules, Extended Release of Dosage 40 mg (US$), 2020
Figure 12-7: Zohydro ER – Price of Oral Capsules, Extended Release of Dosage 50 mg (US$), 2020
Figure 12-8: Global – Zohydro ER Quarterly Sales Q1 – Q4 (US$ Million), 2018
Figure 12-9: Hysingla ER – Available Dosage Strengths (mg)
Figure 12-10: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 20 mg (US$), 2020
Figure 12-11: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 30 mg (US$), 2020
Figure 12-12: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 40 mg (US$), 2020
Figure 12-13: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 60 mg (US$), 2020
Figure 12-14: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 80 mg (US$), 2020
Figure 12-15: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 100 mg (US$), 2020
Figure 12-16: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 120 mg (US$), 2020
Figure 12-17: Nucynta ER – Available Dosage Strengths (mg)
Figure 12-18: Global – Price of Nucynta ER Oral Tablets, Extended Release of Dosage 50 mg (US$), 2020
Figure 12-19: Global – Price of Nucynta ER Oral Tablets, Extended Release of Dosage 100 mg (US$), 2020
Figure 12-20: Global – Price of Nucynta ER Oral Tablets, Extended Release of Dosage 150 mg (US$), 2020
Figure 12-21: Global – Price of Nucynta ER Oral Tablets, Extended Release of Dosage 200 mg (US$), 2020
Figure 12-22: Global – Price of Nucynta ER Oral Tablets, Extended Release of Dosage 250 mg (US$), 2020
Figure 12-23: Global – Nucynta ER Annual Sales (US$ Million), 2018 & 2019
Figure 12-24: Global – Nucynta ER Quarterly Sales Q1 – Q4 (US$ Million), 2018
Figure 12-25: Global – Nucynta ER Quarterly Sales Q1 – Q4 (US$ Million), 2019
Figure 12-26: Kadian – Available Dosage Strengths (mg)
Figure 12-27: Kadian – Price of Oral Capsules, Extended Release of Dosage 10 mg/12 to 24 hr (US$), 2020
Figure 12-28: Kadian – Price of Oral Capsules, Extended Release of Dosage 20 mg/12 to 24 hr (US$), 2020
Figure 12-29: Kadian – Price of Oral Capsules, Extended Release of Dosage 30 mg/12 to 24 hr (US$), 2020
Figure 12-30: Kadian – Price of Oral Capsules, Extended Release of Dosage 40 mg/12 to 24 hr (US$), 2020
Figure 12-31: Kadian – Price of Oral Capsules, Extended Release of Dosage 50 mg/12 to 24 hr (US$), 2020
Figure 12-32: Kadian – Price of Oral Capsules, Extended Release of Dosage 60 mg/12 to 24 hr (US$), 2020
Figure 12-33: Kadian – Price of Oral Capsules, Extended Release of Dosage 80 mg/12 to 24 hr (US$), 2020
Figure 12-34: Kadian – Price of Oral Capsules, Extended Release of Dosage 100 mg/12 to 24 hr (US$), 2020
Figure 12-35: Kadian – Price of Oral Capsules, Extended Release of Dosage 200 mg/12 to 24 hr (US$), 2020
Figure 12-36: Arymo ER – Available Dosage Strengths (mg)
Figure 12-37: Global - Price of Arymo ER Oral Tablets, Extended Release of Dosage 15 mg/8 to  12 hr (US$), 2020
Figure 12-38: Global - Price of Arymo ER Oral Tablets, Extended Release of Dosage 30 mg/8 to 12 hr (US$), 2020
Figure 12-39: Global - Price of Arymo ER Oral Tablets, Extended Release of Dosage 60 mg/8 to 12 hr (US$), 2020
Figure 12-40: Global – Arymo ER Quarterly Sales Q2 & Q3 (US$ Million), 2018
Figure 12-41: Xtampza ER – Available Dosage Strengths (mg)
Figure 12-42: Global – Price of Xtampza ER Oral Capsules, Extended Release of Dosage 9 mg (US$), 2020
Figure 12-43: Global – Price of Xtampza ER Oral Capsules, Extended Release of Dosage 13.5 mg (US$), 2020
Figure 12-44: Global – Price of Xtampza ER Oral Capsules, Extended Release of Dosage 18 mg (US$), 2020
Figure 12-45: Global – Price of Xtampza ER Oral Capsules, Extended Release of Dosage 27 mg (US$), 2020
Figure 12-46: Global – Price of Xtampza ER Oral Capsules, Extended Release of Dosage 36 mg (US$), 2020
Figure 12-47: Global – Xtampza ER Quarterly Sales Q1 – Q4 (US$ Million), 2018
Figure 12-48: Global – Xtampza ER Quarterly Sales Q1 – Q4 (US$ Million), 2019
Figure 12-49: MS Contin – Available Dosage Strengths (mg)
Figure 12-50: Global – Price of MS Contin Oral Tablet, Extended Release of Dosage 15 mg/ 8 to 12 hr (US$), 2020
Figure 12-51: Global – Price of MS Contin Oral Tablet, Extended Release of Dosage 30 mg/ 8 to 12 hr (US$), 2020
Figure 12-52: Global – Price of MS Contin Oral Tablet, Extended Release of Dosage 60 mg/ 8 to 12 hr (US$), 2020
Figure 12-53: Global – Price of MS Contin Oral Tablet, Extended Release of Dosage 100 mg/ 8 to 12 hr (US$), 2020
Figure 12-54: Global – Price of MS Contin Oral Tablet, Extended Release of Dosage 200 mg/ 8 to 12 hr (US$), 2020
Figure 12-55: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 20 mg – 0.8 mg (US$), 2020
Figure 12-56: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 30 mg – 1.2mg (US$), 2020
Figure 12-57: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 50 mg – 2mg (US$), 2020
Figure 12-58: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 60 mg – 2.4 mg (US$), 2020
Figure 12-59: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 80 mg – 3.2mg (US$), 2020
Figure 12-60: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 100 mg – 4 mg (US$), 2020
Figure 13-1: Ampyra – Price of Oral Tablet, Extended Release of Dosage 10 mg (US$), 2020
Figure 13-2: Global – Ampyra Quarterly Sales Q1 – Q4 (US$ Million), 2018
Figure 13-3: Global – Ampyra Quarterly Sales Q1 – Q4 (US$ Million), 2019
Figure 13-4: Global – Ampyra Total Sales (US$ Million), 2018 & 2019
Figure 13-5: Tecfidera – Available Dosage Strengths (mg)
Figure 13-6: Tecfidera - Price of Oral Capsule, Delayed Release of Dosage 120 mg (US$), 2020
Figure 13-7: Tecfidera - Price of Oral Capsule, Delayed Release of Dosage 240 mg (US$), 2020
Figure 13-8: Global – Tecdifera Quarterly Sales Q1 – Q4 (US$ Million), 2018
Figure 13-9: Global – Tecdifera Quarterly Sales Q1 – Q3 (US$ Million), 2019
Figure 13-10: US - Tecdifera Quarterly Sales Q1 – Q3 (US$ Million), 2018 & 2019
Figure 13-11: Rayos – Available Dosage Strengths (mg)
Figure 13-12: Rayos - Price of Oral Tablet, Delayed Release of Dosage 1 mg (US$), 2020
Figure 13-13: Rayos - Price of Oral Tablet, Delayed Release of Dosage 2 mg (US$), 2020
Figure 13-14: Rayos - Price of Oral Tablet, Delayed Release of Dosage 5 mg (US$), 2020
Figure 13-15: Global - Rayos Quarterly Sales Q1 – Q4 (US$ Million), 2018
Figure 13-16: Global - Rayos Quarterly Sales Q1 – Q4 (US$ Million 2019
Figure 13-17: Vumerity – Price of 231 mg Bottle, Delayed Release (US$), 2020
Figure 13-18: Global – Vumerity Fourth Quarter Sales Q4 (US$ Million), 2019
Figure 14-1: Glumetza – Available Dosage Strengths (mg)
Figure 14-2: Global – Price of Glumetza Oral Tablets, Extended Release of Dosage 500 mg (US$), 2020
Figure 14-3: Global – Price of Glumetza Oral Tablets, Extended Release of Dosage 1000 mg (US$), 2020
Figure 14-4: Glucotrol XL – Available Dosage Strengths (mg)
Figure 14-5: Global – Price of Glucotrol XL Oral Tablets Extended Release of Dosage 2.5 mg (US$), 2020
Figure 14-6: Global – Price of Glucotrol XL Oral Tablets Extended Release of Dosage 5 mg (US$), 2020
Figure 14-7: Global – Price of Glucotrol XL Oral Tablets Extended Release of Dosage 5 mg (US$), 2020
Figure 14-8: Global – Price of Glucotrol XL Oral Tablets Extended Release of Dosage 10 mg (US$), 2020
Figure 14-9: Global – Price of Glucotrol XL Oral Tablets Extended Release of Dosage 10 mg (US$), 2020
Figure 14-10: Fortamet – Available Dosage Strengths (mg)
Figure 14-11: Global – Price of Fortamet Oral Tablets, Extended Release of Dosage 500 mg (US$), 2020
Figure 14-12: Global – Price of Fortamet Oral Tablets, Extended Release of Dosage 1000 mg (US$), 2020
Figure 14-13: Glucophage XR – Available Dosage Strengths (mg)
Figure 14-14: Global – Price of Glucophage XR Oral Tablet, Extended Release of Dosage 500 mg (US$), 2020
Figure 14-15: Global – Price of Glucophage XR Oral Tablet, Extended Release of Dosage 750 mg (US$), 2020
Figure 14-16: Global – Price of Bydureon Powder for Injection of Dosage 2mg (US$), 2020
Figure 14-17: Global - Bydureon Quarterly Sales Q1 – Q4 (US$ Million), 2018
Figure 14-18: Global - Bydureon Quarterly Sales Q1 – Q4 (US$ Million), 2019
Figure 15-1: Procardia XL – Available Dosage Strengths (mg)
Figure 15-2: Global – Price of Procardia XL Oral Tablet, Extended Release of Dosage 30 mg (US$), 2020
Figure 15-3: Global – Price of Procardia XL Oral Tablet, Extended Release of Dosage 30 mg (US$), 2020
Figure 15-4: Global – Price of Procardia XL Oral Tablet, Extended Release of Dosage 60 mg (US$), 2020
Figure 15-5: Global – Price of Procardia XL Oral Tablet, Extended Release of Dosage 60 mg (US$), 2020
Figure 15-6: Global – Price of Procardia XL Oral Tablet, Extended Release of Dosage 90 mg (US$), 2020
Figure 15-7: Toprol XL – Available Dosage Strengths
Figure 15-8: Global – Price of Toprol XL Oral Tablet, Extended Release of Dosage 25 mg (US$), 2020
Figure 15-9: Global – Price of Toprol XL Oral Tablet, Extended Release of Dosage 25 mg (US$), 2020
Figure 15-10: Global – Price of Toprol XL Oral Tablet, Extended Release of Dosage 50 mg (US$), 2020
Figure 15-11: Global – Price of Toprol XL Oral Tablet, Extended Release of Dosage 50 mg (US$), 2020
Figure 15-12: Global – Price of Toprol XL Oral Tablet, Extended Release of Dosage 100 mg (US$), 2020
Figure 15-13: Global – Price of Toprol XL Oral Tablet, Extended Release of Dosage 100 mg (US$), 2020
Figure 15-14: Global – Price of Toprol XL Oral Tablet, Extended Release of Dosage 200 mg (US$), 2020
Figure 15-15: Global – Price of Toprol XL Oral Tablet, Extended Release of Dosage 200 mg (US$), 2020
Figure 15-16: Adalat CC – Available Dosage Strengths (mg)
Figure 15-17: Global – Price of Adalat CC Oral Tablet Extended Release of Dosage 30 mg (US$), 2020
Figure 15-18: Global – Price of Adalat CC Oral Tablet Extended Release of Dosage 30 mg (US$), 2020
Figure 15-19: Global – Price of Adalat CC Oral Tablet Extended Release of Dosage 60 mg (US$), 2020
Figure 15-20: Global – Price of Adalat CC Oral Tablet Extended Release of Dosage 60 mg (US$), 2020
Figure 15-21: Global – Price of Adalat CC Oral Tablet Extended Release of Dosage 90 mg (US$), 2020
Figure 15-22: Verelan PM – Available Dosage Strengths (mg)
Figure 15-23: Global – Price of Verelan PM Oral Capsule, Extended Release of Dosage 200 mg/24 hr (US$), 2020
Figure 15-24: Global – Price of Verelan PM Oral Capsule, Extended Release of Dosage 300 mg/24 hr (US$), 2020
Figure 15-25: Plendil – Available Dosage Strengths (mg)
Figure 15-26: Global – Price of Plendil Oral Tablet, Extended Release of Dosage 2.5 mg (US$), 2020
Figure 15-27: Global – Price of Plendil Oral Tablet, Extended Release of Dosage 5 mg (US$), 2020
Figure 15-28: Global – Price of Plendil Oral Tablet, Extended Release of Dosage 10 mg (US$), 2020
Figure 15-29: Cardizem LA – Available Dosage Strengths (mg)
Figure 15-30: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 120 mg/24 hr (US$), 2020
Figure 15-31: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 120 mg/24 hr (US$), 2020
Figure 15-32: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 180 mg/24 hr (US$), 2020
Figure 15-33: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 180 mg/24 hr (US$), 2020
Figure 15-34: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 240 mg/24 hr (US$), 2020
Figure 15-35: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 240 mg/24 hr (US$), 2020
Figure 15-36: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 300 mg/24 hr (US$), 2020
Figure 15-37: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 300 mg/24 hr (US$), 2020
Figure 15-38: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 360 mg/24 hr (US$), 2020
Figure 15-39: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 360 mg/24 hr (US$), 2020
Figure 15-40: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 420 mg/24 hr (US$), 2020
Figure 15-41: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 420 mg/24 hr (US$), 2020
Figure 18-1: US –Controlled Release Market Size (US$ Billion), 2019 - 2026
Figure 18-2: US – Population Above & Below 65 Years of Age (%), 2018
Figure 18-3: US – Share in Global Controlled Release Drug Market (%), 2019
Figure 18-4: Europe –Controlled Release Drug Delivery Market Size (US$ Billion), 2019 - 2026
Figure 18-5: Europe – Share in Global Controlled Release Drug Market (%), 2019
Figure 18-6: European Union – Population Above & Below 65 Years (%), 2018
Figure 18-7: European Union – Estimated Cases of Dementia, 2030 & 2050
Figure 18-8: Japan – Population Above & Below 65 Years (%), 2019
Figure 18-9: Japan – Dementia Cases (Million), 2018 & 2025
Figure 19-1: Accelerative Parameters of Controlled Drug Delivery Systems
Figure 19-2:  Major Challenges Faced by Controlled Drug Delivery System
Figure 20-1: Global – Controlled Release Drug Delivery Market Size (US$ Billion), 2019 - 2026

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Allergan
  • Amylin Pharmaceuticals
  • AstraZeneca
  • BioAlliance Pharma
  • Biogen
  • Collegium Pharmaceutical
  • Controlled Therapeutics (Ferring Pharmaceuticals)
  • Cosmo Pharmaceuticals
  • Egalet
  • Elan Corporation
  • Elan Corporation
  • Flamel Technologies
  • GlaxoSmithKline
  • Heron Therapeutics
  • iCeutica
  • Mithra Pharmaceuticals
  • Neurim Pharmaceuticals
  • Novartis
  • Orexigen Therapeutics
  • Otsuka Pharmaceutical
  • Pfizer
  • Purdue Pharma
  • Syntex Pharmaceuticals International
  • Takeda
  • Zealand Pharma
Note: Product cover images may vary from those shown
Adroll
adroll